JCAR 015

Drug Profile

JCAR 015

Alternative Names: anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/CD28/zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; CD28-modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; JCAR 15; JCAR015

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Mar 2017 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) due to incidences of severe neurotoxicity and deaths due to cerebral oedema, and Juno's strategic decision
  • 01 Mar 2017 Discontinued - Phase-II for Acute lymphoblastic leukaemia (Second-line therapy or greater) in USA (IV) due to incidences of severe neurotoxicity and deaths due to cerebral oedema, and Juno's strategic decision
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top